Research on advanced Alzheimer's disease investigates novel ways to restore cognitive function

June 27, 2017 by Ellen Goldbaum, University at Buffalo
Credit: Wikimedia Commons

While most research on Alzheimer's disease (AD) has focused on early diagnosis and treatment, University at Buffalo scientists are studying genetic and epigenetic factors with the ultimate goal of restoring function to patients in the later stages of the disease.

The UB team's research will include studies in mouse models carrying gene mutations for familial AD (where more than one member of a family has the disease) and in human stem cell-derived neurons from AD patients.

Zhen Yan, PhD, principal investigator, and Jian Feng, PhD, co-investigator, both professors in the Department of Physiology and Biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB, have received a five-year, $2 million grant from the National Institutes of Health to conduct preclinical research to tease out genetic and epigenetic factors that cause Alzheimer's disease. Epigenetic factors can change by altering the way that gene promoters, which initiate the copying of genetic information known as transcription, access the cellular machinery that conducts transcription. Such changes may profoundly impact human health.

"We hypothesize that Alzheimer's is produced by a combination of and environmental factors, such as aging," said Yan, "that induce the dysregulation of specific epigenetic processes that, in turn, lead to impaired cognition."

The UB research will explore how that accompany Alzheimer's disease also might help identify a much sought-after biomarker for the disease, which could, in turn, allow for novel treatment.

Numerous clinical trials in recent years have focused on reducing amyloid beta plaque in the brain. So far, such efforts haven't yet translated into improving cognitive function, Yan said.

"Our research, by contrast, will target synaptic function, which is at the root of cognitive function," she explained. "The idea is that this approach will have a more fundamental effect."

She and her colleagues will investigate aberrant histone methylation, an epigenetic process that affects the expression of genes encoding key proteins that allow for signals to be transmitted between neurons.

When this process is dysregulated in Alzheimer's disease, neuronal signaling doesn't function properly, leading to cognitive impairment.

As those with loved ones with Alzheimer's know, even though the patient can easily remember something that happened 20 years ago, the later stages are characterized by a growing inability to recall recently learned information. That kind of short-term memory, Yan explained, is dependent on excitatory transmission in the frontal cortex, mediated by glutamate receptors.

"At the later stages of the , we know that there is a loss of glutamate receptors that are crucial for learning and memory," she said. "When these receptors lose the ability to communicate, there is a loss of cognition. Our research will try to restore gene expression in these glutamate receptors using epigenetic tools, with the ultimate goal of restoring cognitive ."

Explore further: Researchers discover an epigenetic lesion in the hippocampus of Alzheimer's

Related Stories

Researchers discover an epigenetic lesion in the hippocampus of Alzheimer's

January 21, 2014
Alzheimer's disease can reach epidemic range in the coming decades, by the increasing average age of society. There are two key issues for Alzheimer's disease: there is currently no effective treatment and it has been described ...

Antibiotic restores cell communication in brain areas damaged by Alzheimer's disease

November 15, 2016
New research from the Djavad Mowafaghian Centre for Brain Health at UBC has found a way to partially restore brain cell communication around areas damaged by plaques associated with Alzheimer's disease.

Changes in genetic function in the brain linked to Alzheimer's

April 20, 2012
Changes in the epigenome, a structure that controls the function of genes, were found in the brains of Alzheimer's patients.

Epigenetic culprit in Alzheimer's memory decline

February 29, 2012
In a mouse model of Alzheimer's disease, memory problems stem from an overactive enzyme that shuts off genes related to neuron communication, a new study says.

Could blood pressure drugs have a role in Alzheimer's disease treatment?

January 29, 2016
In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer's disease, say researchers at Georgetown University Medical Center (GUMC) and the National ...

Recommended for you

Practice imperfect—repeated cognitive testing can obscure early signs of dementia

July 12, 2018
Alzheimer's disease (AD) is a progressive, neurodegenerative condition that often begins with mild cognitive impairment or MCI, making early and repeated assessments of cognitive change crucial to diagnosis and treatment.

The 'Big Bang' of Alzheimer's: Scientists ID genesis of disease, focus efforts on shape-shifting tau

July 10, 2018
Scientists have discovered a "Big Bang" of Alzheimer's disease – the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.

'Skinny fat' in older adults may predict dementia, Alzheimer's risk

July 5, 2018
A new study has found that "skinny fat—the combination of low muscle mass and strength in the context of high fat mass—may be an important predictor of cognitive performance in older adults. While sarcopenia, the loss ...

Pathway of Alzheimer's degeneration discovered

July 5, 2018
Scientists at the Montreal Neurological Institute and Hospital (The Neuro) of McGill University have used a unique approach to track brain degeneration in Alzheimer's disease, uncovering a pathway through which degeneration ...

Brain study paves way for therapy for common cause of dementia

July 4, 2018
Scientists have uncovered a potential approach to treat one of the commonest causes of dementia and stroke in older people.

Sleep disorder linked with changes to brain structure typical of dementia

July 4, 2018
Obstructive sleep apnoea (OSA) is associated with changes to the structure of the brain that are also seen in the early stages of dementia, according to a study published in the European Respiratory Journal.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.